Remus Pharma. — 360° view

Remus Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹614 crore and net profit of ₹25 crore for the September 2026 quarter.

Remus Pharma. (NSE: REMUS-SM) closed at ₹817.60 on 20 Nov 2026, up 12.4% over the past year. Its market capitalisation is ₹963 crore and it trades at 23.4 times earnings.

Share price
₹817.60 (20 Nov 2026)
Market cap
₹963 Cr (20 Nov 2026)
P/E
23.36 (20 Nov 2026)
Revenue
₹614 Cr (September 2026 quarter)
Net profit
₹25 Cr (September 2026 quarter)
ROCE
16.8% (FY26)
ROE
12.2% (FY26)
Book value
₹455 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,039.00 / ₹580.00 (20 Nov 2026)
1-year return
12.4% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: REMUS-SM

Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.